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METHODS AND COMPOSITIONS FOR
OPTIMIZING BLOOD AND TISSUE
STABILITY OF CAMPTOTHECIN AND
OTHER ALBUMIN-BINDING THERAPEUTIC
COMPOUNDS

mised the clinical utility of the camptothecins, as continuous
exposures to the active lactone form are requisite for e?icacy
purposes.

In human blood and tissues, the camptothecins exist in a
equilibrium of active lactone form vs. inactive carboxylate
form and the directionality of this equilibrium can be greatly
affected by the presence of human serum albumin (HSA).
Time-resolved ?uorescence spectroscopic measurements
taken on the intensely ?uorescent camptothecin lactone and

CROSS-REFERENCE TO RELATED
APPLICATIONS

camptothecin carboxylate species have provided direct infor

This application claims the bene?t of US. Provisional
Application Ser. No. 60/276,908, ?led Mar. 20, 2001.

mation on the differential nature of these interactions With

FIELD OF THE INVENTION

moderate af?nity yet the carboxylate form of camptothecin

HSA. The lactone form of camptothecin binds to HSA With

binds tightly to HSA, displaying a 150-fold enhancement in
its a?inity for this highly abundant serum protein. Thus, When

The invention relates in general to methods of optimizing

camptothecin and other albumin-binding compounds for

the lactone form of camptothecin is added to a solution con

therapeutic use, and in particular to a method of using human
serum albumin binding compounds to increase the stability
and effectiveness in humans of camptothecin compounds and
other albumin-binding compounds Which have been shoWn to
possess important therapeutic attributes, such as anti-cancer
activity, in murine cells or other in vitro studies, but Which
have been far less successful in humans due to rapid lack of
stability in human plasma. In addition, the invention relates to

taining HSA, the preferential binding of the carboxylate form

the use of human serum albumin binding compounds in con

to HSA drives the chemical equilibrium to the right, resulting
in the lactone ring hydrolyZing more rapidly and completely
20

than When camptothecin is in an aqueous solution Without

25

HSA. In turn, this effect has negatively impacted the topoi
somerase I inhibitory activity of many camptothecins and, by
extension, negatively affects their clinical utility.
The important role that HSA plays in the stability of the
camptothecins varies relative to drug structure. For drugs

junction With camptothecin compounds and other therapeutic

such as camptothecin and 9-aminocamptothecin, HSA func

agents that bind to human serum albumin in methods of
treating or enhancing treatments against diseases such as

tions as a biological sink for the carboxylate form. As a result,

in Whole human blood, 5.3% of camptothecin and only 0.5%
of 9-aminocamptothecin remain in the lactone form at equi

cancer and/ or HIV.
30

BACKGROUND OF THE INVENTION

librium. In contrast, A, B-ring substitutions of CPT, speci?
cally at the 7- and 10-positions, can inhibit the preferential

binding interactions betWeen the camptothecin carboxylate
Camptothecin (CPT) has been shoWn to inhibit the groWth
of a variety of animal and human tumors. Camptothecin and
its related congeners display a unique mechanism of action:

35

and HSA. Accordingly, camptothecin congeners such as
topotecan and SN-38, the biologically active form of the
prodrug CPT-11, display lactone levels at equilibrium of

they stabiliZe the covalent binding of the enZyme topoi

11.9% and 19.5%, respectively. Ultimately, by modulating

somerase I (topo I), an intranuclear enZyme that is overex

the circulatory and tissue levels of free and active camptoth
ecin drug, HSA can negatively impact the anti-cancer e?icacy

pressed in a variety of tumor lines, to DNA. This drug/en

Zyme/DNA complex leads to reversible, single strand nicks
that, according to the fork collision model, are converted to
irreversible and lethal double strand DNA breaks during rep
lication. Therefore, due to the mechanism of its cytotoxicity,

of the camptothecin agent.
40

The effect of serum albumins on camptothecins also differs

45

markedly betWeen loWer vertebrates and humans and this
variance has obscured the judicious selection of analogs for
advancement to clinical trials. These interspecies difference
have lead to signi?cant anomalies When the data from animal
models and clinical studies are compared. In particular,

healthy tissues. Thus, the overexpression of topo I combined

9-aminocamptothecin has displayed striking activity in

With the faster rate of cell replication provide a limited basis

50

murine models bearing brain tumors. HoWever, the pharma
cokinetics of 9-aminocamptothecin in mice are quite differ
ent from those in humans; notably, 9-aminocamptothecin
lactone levels are approximately 100-fold higher in murine

CPT is S-phase speci?c, indicating that it is only toxic to cells
that are undergoing DNA synthesis. Rapidly replicating cells
like cancerous cells spend more time in the S-phase relative to

for selectivity via Which camptothecins can effect cytoxicity
on cancerous cells rather than healthy ho st tissues. It is impor
tant to note that due to the S-phase speci?city of the camp

tothecins, optimal inhibition of topo I requires continuous

blood relative to human blood. This discrepancy is due to the

exposure to the camptothecin agent.
A closed alpha-hydroxy lactone (E) ring of CPT is an
essential structural feature. An intact ring is necessary for the

reduced binding of the carboxylate form of 9-aminocamp

diffusion of the electroneutral form of the drug across mem

tothecin to murine albumin. The logical extension of this
?nding is that approximately 100-fold more free lactone,
55

brane barriers and into cells by passive transport and, directly

barrier, is present in the mouse than it is in humans. The
clinical relevance of this interspecies variation is underscored

relevant to its in vivo anti-tumor potency, is required for the
successful interaction of CPT With the topoisomerase I target.

This essential lactone pharmacophore hydrolyZes under
physiological conditions (pH 7 or above) and, therefore, the
drug can exist in tWo distinct forms: 1) the biologically active,

ring-closed lactone form; and 2) the biologically-inactive,
ring-open carboxylate form of the parent drug. Unfortunately,
under physiological conditions the drug equilibrium favors
hydrolysis and, accordingly, the carboxylate form of the
camptothecin drug persists. The labile nature of this alpha
hydroxy lactone pharmacophore has signi?cantly compro

Which is able to cross cell membranes or the blood-brain

by a recent trial: 99 brain cancer patients Were treated intra
60

venously With 9-aminocamptothecin; the therapy Was grossly
ineffective (one partial responder) due to the likelihood that
99.5% of the drug Was in the carboxylate form, bound to HSA
and unable to transverse the blood-brain barrier.

The inherent blood instability of camptothecin has resulted
65

in an extensive research effort to surmount the problem.
Efforts to realiZe a blood stable camptothecin agent With

potent anti-tumor activity have been primarily focused on
formulation, such as liposomal preparations of the drug, and

US 7,69l,872 B2
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rational drug design, such as the development of the class of
beta-hydroxy lactone camptothecins known as the

the ability to bind to one or more binding sites on human

homocamptothecins. The Work described herein describes a
third approach to maintaining a potent and more blood stable

albumin can become more stable When administered and thus

camptothecin congener: the modulation of camptothecin

Without such additive binding compounds.

drug binding to HSA by implementing competing molecules

It is still further an object of the present invention to pro
vide a method of treating cancer Wherein a camptothecin

serum albumin so that the compounds having high a?inity for
are far more effective than therapeutic drugs administered

that also bind HSA.
The camptothecins are not unique in their ability to bind
albumin, as a variety of small molecules interact With this

compound is administered in conjunction With an appropriate
human serum albumin binding agent.
It is still further an object of the present invention to pro
vide a method of treating HIV infection Wherein a protease
inhibitor is administered in conjunction With an appropriate
human serum albumin binding agent.

protein. A relatively large protein, 67 kD, albumin is distrib
uted both in the plasma and in the interstitial ?uid. Being one

of the most abundant plasma proteins, its circulatory level
ranges from 35 to 50 mg/ml (approximately 0.6 mM). The
principal biological function of HSA is to maintain colloid
osmotic pressure in the vascular system and to transport fatty
acids and bilirubin. HoWever, by hydrophobic and/or ionic
interactions, a variety of small molecules bind tightly to albu
min. Electroneutral and basic drugs may bind to albumin by
hydrophobic binding interactions, and, as albumin has a net
cationic charge, anionic drugs bind avidly to albumin via

It is even further an object of the present invention to

provide a Wide range of compounds Which can effectively be

used to increase and optimiZe the stability of camptothecin
compounds When administered to humans.

20

electrostatic interactions. Albumin possesses tWo Well-char

It is even further an object of the present invention to
provide a method of utiliZing an agent Which can bind to one
or more sites on human serum albumin and yet Which also has
anti-tumor or tumoricidal effects and Which can thus be

acteriZed binding pockets, as Well as other general binding
sites. Site I is knoWn as the Warfarin binding site, Which also

administered in conjunction With camptothecin compounds

binds drugs such as phenylbutaZone, sulfonamides, pheny

camptothecin compounds.

toin, and valproic acid. Site 11 is referred to as the diaZepam

so as to even further enhance the cancer-?ghting properties of
25

It is even further an object of the present invention to
provide a method of utiliZing an agent Which can bind to one
or more sites on human serum albumin and yet Which also has
anti-HIV abilities and Which can thus be administered in
conjunction With protease inhibitors so as to even further

30

enhance the HIV-?ghting properties of protease inhibitors.

site, Which is also the binding site for benZodiaZepines, tryp

tophan, ibuprofen, naproxen, octanoic acid, clo?bric, iopan
ice, probenecid, semi-synthetic penicillins and medium chain
fatty acids. Other general binding sites include sites for biliru
bin, digitoxin and a variety of fatty acids. Recent X-ray crys

tallography and competition data obtained by the present

It is even further an object of the present invention to
provide a method of utilizing an agent Which can bind to one

inventors reveal that camptothecin carboxylate preferentially
associates With a characteriZed drug binding site in subdo
main IB, Which overlaps With one of the main long-chain fatty
acid binding sites, protoporphyrin and other drugs and com

or more sites on human serum albumin and yet Which also has
anti-HIV effects and Which can thus be administered in con
35

junction With camptothecin compounds so as to even further

pounds, although it possesses secondary a?inity to binding

enhance the HIV-?ghting properties of camptothecin com

sites I and II. Interestingly, in vivo small molecule binding to
albumin is saturable at therapeutically relevant drug levels.

pounds.
These and other objects are achieved via the present inven

tion Which implements combination therapy consisting of

The ability of human serum albumin to avidly bind to a

variety of small molecules offers the possibility of competi
tively attenuating the negative effects human serum albumin

40

(HSA) and thereby inhibit albumin binding of drugs Which
have a high binding a?inity for human serum albumin, such as

on the in vivo anti-cancer and/ or anti-HIV activity of camp
tothecin compounds and numerous other compounds such as

camptothecin compounds and protease inhibitors, and thus

camptothecin that have extremely high binding af?nity for
human serum albumin.

competitor molecules that can bind human serum albumin

increase the effectiveness and safety of these drugs When
45

HoWever, no prior methods have recogniZed or attempted
to deal With the problem caused by the human serum albumin

administered to humans. This invention overcomes multiple
obstacles that have been associated With therapies based on

drugs such as camptothecin Which have high binding a?inity

binding activity, and thus methods and compositions are

for human albumin. First, as a result of this binding interac

needed Which can attenuate the negative effects of human
serum albumin on the stability of compounds such as camp

tion, the competitor effects elevated free camptothecin drug
50

tothecin compounds, e.g., camptothecin or 9-aminocamp

levels in human blood and tissues. Secondly, this invention
also overcomes the negative effects of human serum albumin
on the in vivo stability of some camptothecin drugs, such as

tothecin, and other compounds or drugs, such as protease
inhibitors, Which have a high a?inity for human serum albu

camptothecin, 9-aminocamptothecin, and 9-nitrocamptoth

min.

55

SUMMARY OF THE INVENTION

ecin. For camptothecin, 9-aminocamptothecin, and 9-nitro
camptothecin, it has been demonstrated that the inactive,
carboxylate form of the drug binds tightly to human serum
albumin. This binding promotes a shift in the lactone/car

It is thus an object of the present invention to utiliZe human
serum albumin binding molecules in a method of achieving
increased stability of compounds, such as camptothecin com
pounds, Which have a high a?inity for human serum albumin
and Which are thus generally less effective than optimal When
administered in the human bloodstream.
It is also an object of the present invention to provide

therapeutic methods of administering compounds such as
camptothecin that have a high a?inity for albumin in humans
by adding a human serum albumin binding compound With

60

boxylate equilibrium to favor the formation of the carboxy
late form of the drug. A competitor molecule that reduces the
binding of camptothecin carboxylate to human serum albu
min can shift the drug equilibrium to favor re-lactoniZation of
the camptothecin agent. As the equilibrium shifts to favor the
formation of the active, lactone form of the camptothecin

agent, the anti-tumor activity of the drug is preserved. Third,
65

preservation of the electroneutral, lactone form of the camp
tothecin agent should enhance the cellular uptake and cellular
concentration of the agent, as on the electroneutral drug spe

US 7,691,872 B2
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cies may transverse the plasma membrane. Thus, the present
invention provides a method for improving camptothecin

nate negative effects of human serum albumin on the in vivo

anti-cancer and/or anti-HIV capabilities of camptothecin
compounds and other therapeutic compounds such as pro

based anti-cancer and/ or anti-HIV therapies.

The competitive displacement of the camptothecin drug

tease inhibitors Which have high a?inity for human serum

can occur by allosteric inhibition or by direct binding of the

albumin via one or more binding sites on serum albumin.

small molecule to the camptothecin binding pocket(s). The
camptothecin agents herein can include camptothecin, 9-ni
droxy-o-lactone camptothecins, such as the homocamptoth
ecins and homosilatecans, and any other camptothecin agent

Because the human serum albumin binding sites and their
a?inity for many small molecules have been Well character
iZed, many of these small molecules are ideal for in vivo
administration and Will be useful in the present invention and

that physically interacts With human serum albumin either in
its lactone or carboxylate form. The competing small mol

particularbinding sites. A number of suitable small molecules

trocamptothecin, 9-aminocamptothecin, SN-38, the [3-hy

can be utiliZed When it is necessary to target one or more

ecule can include a diverse array of molecular entities that

can thus be employed as human serum albumin binding com

exhibit a binding a?inity for human serum albumin.

petitors to effect the displacement of camptothecin drugs and

Examples include aspirin, ibuprofen, AZT, methotrexate,

compounds, either in the lactone or carboxylate form, and of
other therapeutic compounds, such as protease inhibitors,
Which also have high binding a?inity to human serum albu
min. Generally, it is contemplated that treatment With albu
min binding compounds in accordance With the present

Warfarin, and the medium chain triglycerides, such as capry
late. The patient may be administered a single competitor or
a series of distinct competitors, Which can be administered
individually or as a mixture. The camptothecin agent and the
competitor(s) can be co-administered or administered sepa

20

rately in order to enhance the desired therapeutic effect. The
camptothecin agent and the competitor(s) can be adminis
tered orally and/ or intravenously in order to enhance the

greater binding With HSA.

X-ray crystallographic experiments performed using appa

desired therapeutic effect.
Another important aspect of the present invention is the use

25

of this type of drug displacement therapy utiliZing binding

30

effectiveness and/or safety of drugs or therapeutic com

pounds Which, other than camptothecin, also shoW binding

35

a?inity for human serum albumin. Of the top 200 pharma
ceuticals as of 1999, a substantial number have high binding
a?inity for albumin and in most cases become at least 97%
bound to albumin in the human patient. As a result, the effec
tiveness of these drugs can be severely limited in some cases,

40

serum albumin, or other therapeutic compounds to human
serum albumin, Will thus enhance free drug levels of that
therapeutic compound in the blood and tissue. Given that a
diverse assortment of small molecules binds to HSA, these

With the camptothecin agent or other therapeutic compound
to enhance their free drug levels. Moreover, via inhibiting the
binding of the carboxylate form of a camptothecin drug, a
shift in the equilibria occurs that favors the formation of the

biologically active and electroneutral lactone species. Lastly,
as many of these small molecules exhibit pharmacological

activity, they may be utiliZed dually for their competitive
45

because many drugs are tested ?rst in vitro or in environments

outside the human body Wherein the presence of human
serum albumin is not provided for. As a result, many neWly

developed drugs Work extremely Well in these initial tests, but

solution chemistry.
Inhibiting the binding of the camptothecin agent to human

small molecules may be administered singly or as a mixture

or far greater doses are necessary to achieve a desired result,

and these inordinately higher doses almost invariably lead to
greater drug side-effects Which can often negate the therapeu
tic bene?t of the drugs.
The high binding a?inity in many drugs for albumin also
has created problems in developing effective neW drugs

ratuses and methods previously described in patents such as
U.S. Pat. No. 4,833,233, U.S. Pat. No. 4,886,646 and Us.

Pat. No. 5,585,466, incorporated herein by reference, have
revealed the camptothecin binding sites to be overlapping
With long-chain fatty acids and ibuprofen consistent With the

compounds for albumin for any drug or other bene?cial com

pound Which Will be amenable to improvements in safety (by
loWering the effective dose through displacement) or ef?cacy
by alloWing a higher concentration of the active principle
during therapeutic treatment.
Accordingly, the present invention also is directed to the
addition of an albumin-binding compound to improve the

invention Will be particularly effective With those drugs or
other therapeutic compounds that exhibit about 90% or

50

binding to human serum albumin and for their desired in vivo
effect. Thus, agents such as methotrexate, AZT, and a number
of additional small molecules as set forth beloW may be used
to enhance the free drug levels of camptothecin or other

therapeutic drugs, such as protease inhibitors, and substan
tially enhance their respective biological effects in humans.

then are rendered less effective or entirely useless When

administered to human patients because of their high a?inity

BRIEF DESCRIPTION OF THE DRAWINGS

to human serum albumin Which has not been accounted for. In

addition to the camptothecin compounds set forth in detail

herein, numerous other drugs Will also be improved through
introduction of albumin binding compounds in accordance
With the present invention, including drugs such as protease

55

FIGS. 1-6 re?ect test results With regard to camptothecin

compounds (CPT) and competitor binding agents.
FIG. 1 is a graphic representation of competitor binding

inhibitors Which have shoWn some initial effectiveness in

tests betWeen CPT and ibuprofen.

anti-HIV treatment. In accordance With the present invention,
the anti-HIV treatments that employ protease inhibitors With
a high binding af?nity for albumin Will be greatly enhance
When such treatments Will be administered in conjunction

tests betWeen hCPT and ibuprofen.

FIG. 2 is a graphic representation of competitor binding
FIG. 3 is a graphic representation of competitor binding
tests betWeen SN38 and Caprylic Acid.

With administration of an effective amount of the albumin

binding compounds in accordance With the present invention.
The present invention thus provides a method of utiliZing
the ability of human serum albumin to avidly bind to a variety
of small molecules so as to competitively attenuate or elimi

FIG. 4 is a graphic representation of competitor binding
65

tests betWeen CPT and Caprylic Acid.

FIG. 5 is a graphic representation of competitor binding
tests betWeen SN38 and HSA.
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HSA Binding of the Competitor

FIG. 6 is a graphic representation of competitor binding
tests betWeen hCPT and Caprylic Acid.

The competitor may bind to HSA at speci?c, de?ned sites,
as detailed by crystallographic and displacement studies, and
may also bind HSA at non-speci?c sites that have yet to be

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS

clearly de?ned. Binding betWeen the competitor and HSA
may occur by covalent or non-covalent mechanisms.

For the purpose of clarity in the detailed description of the

General De?nitions
Before the present compositions and methods are disclosed
and described, it is to be understood that this invention is not
limited to speci?c drugs, human serum albumin selective

invention, the following de?nitions and detailed description
of the invention are provided beloW.

Hydrolysis of the Camptothecins
The [3-hydroxy-6-lactone members of the camptothecin

ligands, pharmaceutical carriers, or administration regimens,
as such may, of course, vary. It is also to be understoodthat the

class of anti-cancer drugs exhibit the folloWing chemical
equilibrium at pH 7 and above:

terminology used herein is for the purpose of describing
particular embodiments only and is not intended to be limit

ing.
It must be noted that, as used in the speci?cation and the
Figure l: CPT Hydrolysis at Physiological pH

appended claims, the singular forms “a,” “an,” and “the”
include plural referents unless the context clearly dictates
20

otherWise. Thus, for example, reverence to a “a pharmaco
logically active agent” includes mixtures of tWo or more such

ligands, and the like.
By the term “pharmacologically active agent” or “drug” as

pH : 7.4

25

used herein is meant any chemical material or compound
suitable for administration to a mammalian, preferably
human, individual, Which induces a desired local or systemic

effect. In general, this includes: anorexics; anti-infectives
such as antibiotics and antiviral agents, including many peni

cillins and cephalosporins; analgesics and analgesic combi
nations, antiarrythmics; antiarthritics; antiasthmatic agents;
anticholinergics; anticonvulsants; antidiabetic agents; antidi

arrheals; antihelminthics, antihistamines; anti-in?ammatory
agents; anti-migraine preparations; antinasuseants; antine

oplastics; antiparkinsonism drugs; antipruritics; antipsychot
ics; antipyretics; antisense agents; antispasmodics; cardio
vascular preparations including calcium channel blockers
and beta-blockers such as pindolol; antihypertensives; central

nervous system stimulants; cough and cold preparations,

CPT Carboxylate

including decongestants; diuretics; gastrointestinal drugs;
40

sympathomimetics; hormones such as estradiol and steroids;

The electroneutral lactone species, as depicted on the left,

hypnotics; immunosuppressives; muscle relaxants; parasym

represents the biologically active form of the camptothecin
agent. The carboxylate species, as depicted on the right, rep
resents the biologically inactive forrn of the agent. The [3-hy
droxy-o-lactone camptothecins, also knoWn as the

vasodilators including general coronary, peripheral and cere
bral; xanthine derivatives.

patholytics; psychostimulatants; sedatives; tranquilizers;

homocamptothecins and homosilatecans, also undergo

As used herein, the term “competitor” refers to a chemical
material or pharmacologically active agent suitable for

hydrolysis, hoWever, there is no chemical equilibrium as the
reaction is not reversible under normal physiological condi

petitor exhibits binding af?nity for serum albumin and, in

45

administration to a mammalian, preferably human. The com

tions. The hydrolysis of the [3-hydroxy-6-lactone camptoth
ecins is detailed above.

50

ic);medium chain fatty acids (C6-C14; including caprylate or

HSA Binding of the Carboxylate Species
The carboxylate species of the camptothecin agent may

octanoate); phospholipids (lysolecithins, oleoyllysophospha
tidic acid, phosphatidylcholine, phosphatidylethanolamiine);

bind HSA at speci?c, de?ned sites, as detailed by crystallo

graphic and displacement studies, and may also bind directly

general, includes: long chain fatty acids (Cm-C20; including
oleic, palmitic, linoleic, stearic, arachidonic, and palmitole

55

eicosanoid derivatives (leukotrienes, thromboxanes, prostag
landins A, E, F, and I); steroid hormones (cholesterol, test

to HSA at non-speci?c sites that have yet to be clearly
de?ned. Binding may occur by hydrophobic and/or ionic

osterone, pregnenolone, cortisol, androsterone, indol,
progesterone, estrogen); vitamin D (both monohydroxyvita

interactions betWeen HSA and the camptothecin carboxylate

min D and dihydroxyvitamin D); bile salts (lithocholate,

form.
60

HSA Binding of the Lactone Species
The lactone species of the camptothecin agent may bind
HSA at speci?c, de?ned sites, as detailed by crystallographic
and displacement studies, and may also bind directly to HSA
at non-speci?c sites that have yet to be clearly de?ned. Bind
ing betWeen HSA and the camptothecin lactone form may
occur by non-covalent means.

65

chenodeoxycholate, deoxycholate, ursodeoxycholate, cho
late, glycolitocholate, glycochenodeoxycholate, taurocheno
doxycholate, glycodeoxycholate, glycocholate, taurocho
late); bilirubins (bilirubin, biliverdin, xanthobilirubin,

EZ-cyclobilirubin, o-bilirubin); porphyrins (hematin, proto
porphyrin); Warfarin; salicylates, ibuprofen; prednisone;
iophenoxate; sul?soxaZole; phenylbutaZone; oxphenylbuta
Zone; digitoxin; indomethacin; tolbutamide; furosemide;

phenytoin; chlorpropamide; chlorthiaZide; the penicillins (in

US 7,691,872 B2
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cluding oxacillin, benZylpenicillin); acetotriZoate; isulfobro

Under physiological conditions, the camptothecin drug

mophthalein; deacetylcolchicine; dansylamide; dansyl
glutamine;
dansylsarcosine;
indomethacin;

carboxylate forms. In humanblood and tissues, binding of the

phenylpropaZone; aZobenZene derivatives; sulfobromophtha

camptothecin drug to human serum albumin can occur When

exists in a equilibrium of the active lactone and inactive

lein; triiodobenZoate; benZodiaZepine (including diaZepam);

said drug is either in the biologically inactive, carboxylate

?ufenamate; iopanoate; ethacrynate; panproxen; clo?brate;

form or in the biologically active, lactone form. Camptoth

L-tryptophan; N-acetyl-L-tryptophan; 6-methyltryptophan;

ecin, 9-aminocamptothecin, and 9-nitrocamptothecin bind

thyroxine; 3,5,3'-L-triiodothyronine; indole propionate;
kynurenine; ethacrynate; panproxen; chlorophenoxyisobu

human serum albumin predominantly in the carboxylate
form. In contrast, SN-38, the biologically active agent of the
camptothecin prodrug CPT-l 1, binds human serum albumin

tyrate; 3'aZido-3'-deoxythymidine; non-steroidal anti-in
?ammatory agents containing ionized carboxyl groups; gos

in the lactone form. Binding of the camptothecin drug,

sypol; meso-2,3-dimercaptosuccinic acid; captopril; N-2

Whether in the carboxylate or lactone form, reduces the levels
of free drug in the blood and tissue.
As described above, the present invention relates to the use

mercaptoethyl-l ,2-diaminopropane;
disul?ramacetaminophen, dis-dichlorodiamineplatinum 9II;
pyridoxal 5'-pho sphate; aquocobalamin form of vitamin B 12;
folate; ascorbate (and its oxidation product dehydroascor

of human serum albumin binding molecules Which are

bate); melatonin; ot-melanotropin; gastrin; corticotropin and
methotrexate.
An “effective amount” of a pharmacologically active agent

in order to achieve greater stability in the human bloodstream
and thus alloW for the camptothecin compounds to be more
effective When administered in human treatment regimens.

is intended to mean a nontoxic but su?icient amount of the 20

The invention thus contemplates therapeutic methods, such

agent, such that the desired prophylactic or therapeutic effect
is produced. As Will be pointed out beloW, the exact amount of
a particular agent that is required Will vary from subject to
subject, depending on the species, age, and general condition

as methods to treat diseases such as cancer or HIV, Wherein

of the subject, the severity of the condition being treated, the
particular drug used and its mode of administration, and the

administered in conjunction With camptothecin compounds

camptothecin compounds are administered in humans in con
junction With a suitable human serum albumin binding com
25

like. In addition, other factors, such as an assay of patient

albumin levels prior to administering the therapy and adjust
ing the drug levels accordingly is often utiliZed to properly set
a treatment regiment for a particular patient.
Thus, it is not possible to specify an exact “effective
amoun ” of any particular pharmacologically active agent.
HoWever, an appropriate effective amount may be determined

of additional small molecules as set forth beloW may be used
30

the present invention:
35

By the term “pharmaceutically acceptable” to describe a
carrier or excipient is meant a material that is not biologically
or otherWise undesirable, i.e., the material may be adminis

tered along With the selected pharmacologically active agent
Without causing any desirable biological effects or interacting

to enhance free camptothecin drug levels and substantially
enhance their respective biological effects in humans.
The following is a list of molecules that bind human serum
albumin and are thus contemplated for use in accordance With

for any particular drug by one of ordinary skill in the art using

only routine experimentation.

pound. Even further, it is contemplated that the human serum
albumin binding compound selected for use in accordance
With the present invention Will ideally be one that additionally
enhances the effect of the free camptothecin compounds. In
this regard, agents such as methotrexate, AZT, and a number

Long Chain Fatty Acids (C l6-C2O)
Oleic, palmitic, linoleic, stearic, arachidonic, and palmitoleic
Note for fatty acids, at pH 7 they exist as salts, and thus may
more accurately be de?ned not as palmitic acid but as

40

palmitate.

in a deleterious manner With any of the other components of

Medium Chain Fatty Acids (C6-Cl4)

the pharmaceutical composition in Which it is contained.

Phospholipids:
Lysolecithins, oleoyllysophosphatidic acid, phosphatidyl
choline, phosphatidylethanolamiine

The term “camptothecin drug” or “camptothecin com
pound” is inclusive of camptothecins that contain either an

E-ring ot-hydroxy lactone pharmacophore or an E-ring [3-hy
droxy lactone pharmacophore, Which includes the
homocamptothecins and homosilatecans. As used herein, the

45

Leukotrienes, thromboxanes, prostaglandins A, E, F, andI
Steroid hormones:

camptothecin analogs 9-aminocamptothecin, 10-hydroxy
camptothecin, 10, 1 1-methylenedioxy-camptothecin, 9-nitro
10,1 1 -methylenedioxycamptothecin, 9-chloro-10,1 1-meth
ylenedioxycamptothecin,

methylenedioxycamptothecin,

Eicosanoid derivatives:

Cholesterol, testosterone, pregnenolone, cortisol, androster
50

one, indol, progesterone, estrogen
Vitamin D: both monohydroxyvitamin D and dihydroxyvita
min D.

9-amino-10,1 1 -

9-nitrocamptothecin,

Bile Salts: Lithocholate, Chenodeoxycholate, Deoxycholate,

Ursodeoxycholate, Cholate, Glycolitocholate, Glyco
chenodeoxycholate, Taurochenodoxycholate, Glycode

topotecan, and other analogs of camptothecin, are collec
tively referred to as camptothecin drugs or compounds.
55

DESCRIPTION OF THE INVENTION

oxycholate, Glycocholate, Taurocholate
Bilirubins: bilirubin, biliverdin, xanthobilirubin, EZ-cyclobi
lirubin, o-bilirubin

The present invention accomplishes multiple tasks. First,

Gossypol (note high af?nity 1.1 e-7, competes With bilirubin,
antibiotic, promotes fertility)

administration of a HSA binding competitor elevates free

camptothecin levels in blood and human tissues by inhibiting
camptothecin drugs from binding to human serum albumin.
Secondly, for those camptothecin drugs that bind human

60

serum albumin in the carboxylate form, this invention induces
a shift in the lactone carboxylate equilibrium that enhances in

vivo drug lactone levels. Third, Enhanced free drug levels and
elevated lactone levels in vivo result in greater cellular uptake
and enhanced activity.

65

Porphyrins: hematin, protoporphyrin
Site I Ligands (domain IIA): bilirubin, Warfarin, salicylates,
cyclic eicosanoids, hematin, G-dicarboxylic medium
chain fatty acids, long-chain fatty acids, prednisone, iophe
noxate (eliminated sloWly due to extremely high a?inity,
contrast agent), salicylates, sul?soxaZole, WarfarinS-, phe
nylbutaZone, digitoxin, indomethacin, tolbutamide, furo
semide, phenytoin, chlorpropamide, chlorthiaZide, oxacil

US 7,691,872 B2
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lin, benZylpenicillin, acetotriZoate, phenol red, bromcresol
green, brophenol blue, isulfobromophthalein, methyl

In accordance With the invention, the inhibition of the
binding of the camptothecin agent to human serum albumin
Will thus enhance free drug levels in the blood and tissue.

orange, methyl red, evans blue, deacetylcolchicine, Phenol

red, dansylalmide, dansylglutamine, dansylsarcosine,

Given that a diverse assortment of small molecules binds to
HSA, these small molecules may be administered singly or as
a mixture With the camptothecin agent or compound to
enhance their free drug levels. Additionally, as many of these

indomethacin, phenylpropaZone, bromcresol purple,
aZobenZene derivatives, sulfobromophthalein, triiodoben
Zoate, cibacron blue, various penicillins, benZodiaZepine,
Site II Ligands (subdomain IIA): monocarboxylic medium
chain fatty acids (C6-C14; in particular octanoate), diaZ

small molecules exhibit pharmacological activity, it is also
contemplated they may be utiliZed dually for their competi

epam (the 2,3-benZodiaZepines), ?ufenamate, iopanoate,
ethacrynate, panproxen, chlorophenoxyisobutyrate (clo?
brate), L-tryptophan, octanoate, thyroxine, N-Acetyl-L
tryptophan, indole propionate, kynurenine, 6-methyltryp
tophan, 3,5,3'-L-triiodothyronine, triiodobenZoate,
ibuprofen, chloride ions, AZT (3'aZido-3'-deoxythymi
dine, non-steroidal anti-in?ammatory agents containing

tive binding to human serum albumin and for their desired in
vivo effect. Thus, agents such as methotrexate, AZT, and a

number of additional small molecules Which have therapeutic
effects apart from their ability to bind human serum albumin
are preferably used in accordance With the invention to even

further enhance free camptothecin drug levels and substan

tially improve their respective biological effects in humans.

ioniZed carboxyl groups (Li et al., 1988; WanWimolruk et

These biological effects include their use as anti-cancer and/

al., 1991), oxphenylbutaZone

or anti-HIV agents, as Well as their use in any other anti

Ligands at CySH-34: penicillamine, meso-2,3-dimercapto
succinic acid, captopril (N -2-mercaptoethyl-1,2-diamino
propane,

disul?ramacetaminophen,

topoisomerase I-based therapy.
20

cis

dichlorodiammineplatinum9II)
Miscellaneous: pyridoxal 5'-phosphate, Aquocobalamin
form of vitamin B12, folate, ascorbate and its oxidation

product dehydroascorbate, melatonin, a-melanotropin,
gastrin, corticotropin, calcium, nickel, magnesium, and

examples Which folloW represent techniques and composi
25

af?nity of a second ligand for albumin to the extent multiple
ligands are used.
In accordance With the invention, the above human serum

tions discovered by the inventors to function Well in the
practice of the invention, and thus can be considered to con

stitute preferred modes for its practice.

copper
It is noted that the binding of some of these molecules to
human serum albumin may be readily folloWed by detection

procedures Well knoWn in the ?eld. For example, binding of
tryptophan may easily be folloWed by ?uorescence. In addi
tion, different ligands may either increase or decrease the

The folloWing examples are provided only to exemplify
various aspects of the preferred embodiments of the present
invention. It Will thus be appreciated by those of skill in the art
that the techniques and compositions disclosed in the

HoWever, those of skill in the art Will also appreciate that

the folloWing examples are only exemplary aspects of the
30

present invention, the scope of Which is de?ned by the claims
appended hereto, and thus many changes can be made in the
speci?c embodiments Which are disclosed and still obtain a
like or similar result Without departing from the spirit and
scope of the invention.

35

albumin binding compounds may be utiliZed in conjunction

EXAMPLES

With human therapies Which can utiliZe camptothecins, and

these albumin binding compounds inhibit binding of camp

Example 1

tothecin compounds to human serum albumin present in

human blood and plasma, Which frees the camptothecin drug
for therapeutic purposes. In addition, it is contemplated that

40

HSA/Competition Experiments by Fluorescence
Spectroscopic Methods

the methods of the present invention may involve admini stra
tion of a cocktail on one or more of these binders, or a single

competing binding agent may be administered as needed.
It is also contemplated that these albumin binding com
pounds may be administered before, during, or after admin
istration of the camptothecin agent. It is also contemplated

45

from Boehringer Ingelhem (Lot#95-002). Dimethyl Sulfox
ide (HPLC grade, Aldrich, MilWaukee, Wis.) Was used to
prepare stock solutions of camptothecin at various concen
trations, Which Were stored in the dark at —200 C. Working

that any camptothecin agent that binds albumin, regardless of
the effect albumin has on the agent, Will still be useful in
accordance With the invention since one goal of the therapy is
to raise the vascular and tissue levels of total free drug, and
this goal Will still be achieved even if albumin has an effect on

50

solutions of 10x10“3 M camptothecin carboxylate and camp
tothecin lactone Were prepared by diluting a stock solution of
camptothecin in DMSO With PBS buffer at pH values of 10.0

and 3.0, respectively. The Sigma Chemical Co. (St. Louis,
Mo.) supplied the human serum albumin (HSA) employed in

the agent.
The present invention thus provides a method of utilizing
the ability of human serum albumin to avidly bind to a variety
of small molecules so as to competitively attenuate negative
effects of human serum albumin on the in vivo camptothecin
compounds’ anti-cancer and anti-HIV activities. Because the
human serum albumin binding site and af?nity for many
small molecules have been Well characterized, many of these
small molecules are ideal for in vivo administration and Will
be useful in the present invention and can be utiliZed When it

Materials and Methods:
The camptothecin used in the experiments Was obtained

55

the binding experiments. A 2.5><10_3 M stock solution of
HSA Was prepared in PBS buffer at a ?nal pH of 7.40:0.05.
The concentration of the HSA Was determined on a Weight

to-volume basis (g/L). A Milli-Q UV PLUS puri?cation sys
tem (Bedford, Mass.) Was used to acquire high-purity Water.
60

For the competition binding experiments, 3.0><10_3 M
camptothecin carboxylate and 10x10‘3 M homocamptoth
ecin Working solutions Were prepared. Caprylic acid obtained

is necessary to target particular binding sites. A number of

from Sigma Chemical Co. (Lot#72HO473) Was one of the

suitable small molecules such as those described above can

competitive binders analyZed. Five different stock solutions

thus be employed as human serum albumin binding competi
tors to effect the displacement of camptothecin drugs and
compounds, either in the lactone or carboxylate form.

65

of varied caprylic acid concentration Were made to satisfy
concentration speci?cations discussed beloW. Another com

petitive binder studied Was Ibuprofen obtained from Sigma
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Chemical Co. (Lot#13HO7511). Four different stock solu
tions of varied ibuprofen concentration Were prepared. Both
caprylic acid and ibuprofen stock solutions Were made-up in

Homocamptothecin carboxylate competition results are
shoWn in Figures hCPT/HSA and hCPT: Caprylic Acid/HSA
and hCPT/HSA and hCPT: Ibuprofen/HSA, respectively.
Background ?uorescence from the HSA Was detected in all

PBS buffer at a ?nal pH of 7401005.

of the experiments. In the camptothecin carboxylate compe
tition experiments With caprylic acid and ibuprofen, the maxi

Fluorescence Spectroscopy:

mum scattered light detected Was 8% and 5%, respectively.

Steady-state ?uorescence anisotropy measurements Were

The homocamptothecin carboxylate competition experi

recorded using a SLM 9850 ?uorometer interfaced With an
IBM computer. The samples Were excited at an excitation

ments displayed higher values of maximum scatter equal to
13% and 15% for the caprylic acid and ibuprofen competi
tion. In all cases, the percent of scattered light decreased With

Wavelength of 370 nm by implementing an argon ion laser.
The excitation monochromator bandWidth Was set to 4 nm.

increasing competition concentration.

Fluorescence emission Was isolated from scattered light by

utiliZing 400 nm long band-pass ?lters.

Example 2

For the camptothecin and homocamptothecin binding
experiments With HSA, fourteen test tubes of varied HSA
concentration Were prepared. Volumes of the 2.5><10_3 M

Procedure of Competition Binding and Stability of
9AC, DB172, DB67 and SN38 With the Presence of

HSA stock and PBS buffer pH of 7.40:0.05 Were combined
in fourteen test tubes to create different HSA concentrations

Various Drugs

ranging from 0.5><10_5 M to 1.8><10_4M. The test tubes Were
placed in a WWR Scienti?c Waterbath (Model 1235) set at

1. Materials

37° C. for approximately ?ve minutes. FolloWing this, the

Samples of 9AC, DB67, DB172 and SN38 Were obtained

?rst test tube Was removed and a 5 0x10“6 M concentration of

from various sources. Human serum albumin (HSA) Was

the drug Was prepared by adding an appropriate volume of the

purchased from Sigma Chemical (St. Louis, Mo.). Recovered

1.0><10_3 M camptothecin or homocamptothecin (37° C)
Working solution to the test tube. The drug and HSA solution

25

Was immediately vortexed on a Vortex Genie 2TM from Fisher

Scienti?c for approximately three to ?ve seconds. Immedi
ately after, the solution Was transferred to a thermostatic (37°

C.) sample cell and the anisotropy measurement Was
recorded. The same procedure Was folloWed for the remain

30

drug. This short acquisition time secured that the anisotropy
35

prepared inA.C.S. spectrophotometric grade dimethylsulfox
ide (DMSO; Aldrich, MilWaukee, Wis., USA) at a concentra
tion of 2x10“3 M and stored in the dark at —20° C. until use.

results of the camptothecin and homocamptothecin HSA
binding experiments can be seen in the Figures.
The procedure folloWed for the competition binding
experiments Was very similar to the description above. A

Millipore. (Centrifree; MW cutoff 30,000). Triethylamine
and HPLC-grade acetonitrile Was purchased from Fisher Sci

enti?c (Fair LaWn, N.J., USA). High purity Water Was pro
vided by a Milli-Q UV Plus puri?cation system (Millipore,
Bedford, Mass., USA). Stock solutions of each drug Were

ing thirteen test tubes. For each tube, the anisotropy measure
ment Was recorded Within one minute upon the addition of the

measurements re?ected the initial form of the drug added
instead of a lactone-carboxylate equilibrium form. The

human plasma Was obtained from Central Kentucky Blood
Center (Lexington, Ky.) and stored at —20° C. Whole human
blood Was obtained from a healthy male donor by draWing
blood into sterile vacutainers containing heparin, to prevent
clot formation. Ultra?ltration tubes Were purchased from

Phosphate buffered saline (PBS, pH 7.4) refers to an aqueous
solution of 8 mM dibasic sodium phosphate (Na2HPO4), 1
40

3.0><10_3M camptothecin carboxylate Working solution Was

mM potassium phosphate monobasic crystal (KH2PO4), 137
mM sodium chloride (NaCl) and 3 mM potassium chloride

prepared and kept at 37° C. Only ten of the fourteen test tubes

(KCl).

described above Were prepared. The HSA concentration var
ied from 5.0><10_6 to 75x10‘5 M. The maximum HSA con
centration Was reduced due to background ?uorescence
present from the HSA. Once the HSA/PBS solutions Were
prepared, an appropriate volume of a competitor stock Was
added to each tube. The competitor concentration Was iden

2. HPLC apparatus:
All HPLC analyses Were carried out on a Waters Alliance
45

out on a Waters symmetry® C18 5 pm 3.9><150 mm column

With a Waters symmetry® C18 5 pm 3.9><20 mm guard col

tical for all ten test tubes. Caprylic acid competition concen

trations of1.0><10_4 M, 1.0><10_3 M, 5 0x10“3 M, 1.0><10_2 M
and 5.0><10_2M Were studied using the stock solutions dis
cussed earlier. The same competition concentrations for Ibu
profen Were studied excluding the 1 .0><10_2M. Once the com
petitor Was added, the test tubes Were placed in the Waterbath,
like before, and the measurements Were taken by employing
the same technique described for the HSA binding experi
ment. The results for the caprylic acid and ibuprofen compe
tition binding With camptothecin carboxylate are shoWn on

Figures CPT/HSA and CPT: Caprylic Acid/HSA and CPT/
HSA and CPT: Ibuprofen/HSA, respectively.

50

umn. For the separation of 9AC, Which is higher ?uorescence
at loW pH and the acidi?cation of mobile phase before sepa
ration Will change 9AC carboxylate form to lactone form, the

postcolumn acidi?cation Was employed. The postcolumn
55

acidi?cation can separation carboxylate and lactone before
acidify and acidify the mobile phase by pump 0.5N HCl at a
?oW rate 0.5 ml/min before the drug goes into the detector. A
XterraTM MS Cl 8 5 pm 3.9><150 mm column (stable at loW and

high pH) Was used for postcolumn acidi?ation to stable the
baseline. For the separation of 9AC, mobile phase consisted
of 20% acetonitrile and 80% of an aqueous buffer containing
60

The homocamptothecin carboxylate competition experi

triethylamine and acetate. The triethylamine/acetate buffer
(pH 5.5) contained 2% triethylamine added to distilled,
deioniZed Water With pH adjustment to 5.5 made With con

ments Were carried out using a 10x10“3 M homocamptoth
ecin carboxylate Working solution at 37° C. Ten test tubes

centrated acetic acid. Fluorescence excitation for 9AC Was set
at 380 nm and emission at 450 nm. For DB172, the mobile

Were prepared using the same procedure described for the

camptothecin competition experiments. Caprylic acid and

2690 Separations Module equipped With a WatersTM 474
Scanning ?uorescence Detector, All separations Were carried

ibuprofen competition concentrations of 10x10‘4 M, 10x

phase consisted of 57% acetonitrile and 43% triethylamine/
acetate buffer. Excitation and emission detectors settings of

10'3 M, 5.0><10_3 M, and 50x10“2 M Were studied.

371 nm and 428 nm, respectively, Were used. For DB67, the
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mobile phase consisted of 41% acetonitrile and 59% triethy

The bound concentration Was obtained by calculating differ

lamine/acetate buffer. Excitation and emission detectors set
tings of 380 nm and 560 nm, respectively, Were used. For

ence: corrected total concentration minus free concentration.
All experiments Were run in triplicate.

SN38, the mobile phase consisted of 25% acetonitrile and
75% triethylamine/acetate buffer. Excitation and emission

Protein Binding Studies of DB67 Carboxylate
The present studies determined the protein binding to the

detectors settings of 383 nm and 560 nm, respectively, Were
used. FloW rates of l min/ml Were used in all experiments.

carboxylate form of DB67. Initial experiments Were run to

determine the amount of DB67 carboxylate lost during pro
tein binding studies due to adhesion to the ultra?ltration
membrane. PBS (990 pl) at pH 7.4 Was spiked With DB67
carboxylate to form 1 pM DB67 solution. After vortexing for

The mobile phase Was degassed by ?lter through a membrane
?lter (0.45 pm, Millipore). Fluorescence output signal Was

monitored and integrated using Millennium32 Chromatogra
phy Manager softWare.

30 seconds, 500 pl of the solution Was transferred to an
ultra?ltration device and centrifuged for 15 minutes at 4500
rpm. A 100 pl aliquot of the ?ltrate Was added to 600 pl
ice-cold methanol and vortexed. A 500 pl aliquot of the super
natant Was removed diluted With 500pl PBS (pH 12) and
injected (10 pl) onto the HPLC. The same protocol Was

3. Protein Binding Studies:

Preparation of Standard Solution
A stock solution containing 2 mM of the drug of the interest
in DMSO Was prepared and stored at —200 C. For 9AC and
DB67, an aliquot of this stock Was added to PBS pH 10.0 to

repeated With 100 pl total (1 pM DB67 before ultra?ltration).

form 100 pM carboxylate standard solutions.

tion divided by the total concentration.

The percentage recovery Was obtained: the ?ltrate concentra
20

Protein Binding of DB67 Carboxylate to HSA (30 mg/ml),

Protein Binding Studies of 9-AC Carboxylate
The present studies determined the protein binding to the

Human Plasma With or Without the Presence of Caprylic Acid

Protein binding studies using HSA, human plasma With

carboxylate form of 9-AC. Initial experiments Were run to

determine the amount of 9-AC carboxylate lost during protein

25

binding studies due to adhesion to the ultra?ltration mem

brane. PBS (990 pl) at pH 7.4 Was spiked With 9-AC carboxy
late to form 1 pM 9-AC solution. After vortexing for 30
seconds, 500 pl of the solution Was transferred to an ultra?l
tration device and centrifuged for 15 minutes at 4500 rpm. A
100 pl aliquot of the ?ltrate Was added to 600 pl ice-cold

form different concentration of drug, In the test tube, 990 pl
HSA solution or human plasma With or Without various Was
30

Was removed and mixed With 25 pl 12 N HCl. The suspension

Was mixed With 1 ml of Water, vortexed, and injected (100 pl)
35

total (1 pM 9-AC before ultra?ltration). The percentage

8000 rpm for 30 seconds. A 500 pl aliquot of the supernatant
Was removed and diluted With 500 pl PBS (pH 12) and
injected (10 pl) onto the HPLC. The same protocol Was

repeated With 100 pl total (1 pM DB67 before ultra?ltration).

recovery Was obtained: the ?ltrate concentration divided by
the total concentration.

Protein Binding of 9-AC Carboxylate to HSA (30 mg/ml),

spiked With DB67 carboxylate to form 1 pM DB67 solution.
After vortexing for 30 seconds, 500 pl of the solution Was
transferred to an ultra?ltration device and centrifuged for 15
minutes at 4500 rpm. A 100 pl aliquot of the ?ltrate Was added
to a 600 pl ice-cold methanol, vortexed and centrifuged at

methanol and vortexed. A 500 pl aliquot of the supernatant
onto the HPLC. The same protocol Was repeated With 100 pl

and Without the presence of various drugs Were conducted in
a similar manner. HSA Were prepared With PBS (pH 7.4). A
mount of caprylic acid Was added to HSA or human plasma to

The total drug concentration Was corrected for the apparent
drug loss due to adsorption of the drug to the ultra?ltration
40

membrane using the equation:

Human Plasma With or Without the Presence of Various
Corrected total cOncentratiOnIdeteImined total con

Drugs.

centrationxthe percentage recovery.

Protein binding studies using HSA, human plasma With
and Without the presence of various drugs Were conducted in
a similar manner. HSA Were prepared With PBS (pH 7.4). A

45

mount of different drug (phenylbutaZone, ibuprofen, caprylic
acid , aspirin, Warfarin-Na salt, L-tryptophan) Was added to
HSA or human plasma to form different concentration of

drug, In the test tube, 990 pl HSA solution or human plasma

50

500 pl of the solution Was transferred to an ultra?ltration
55
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100 pl total (1 ppM 9-AC before ultra?ltration). The total

centrationxthe percentage recovery.

added to 798 pl PBS pH 10.0 to form 1 pM carboxylate form,
and injected onto the column. The ratio of molar ?uorescence
intensities of the lactone to carboxylate form (k) is calculated
as folloWing:
Lactone/carboxylate ratio (k):average peak area of
lactone/average peak area of carboxylate

Stability Study of 9AC, DB67, DBl72 and SN38 in Human

drug concentration Was corrected for the apparent drug loss
due to adsorption of the drug to the ultra?ltration membrane
Corrected total concentration:detennined total con

Lactone and Carboxylate Peak Area Ratio
A stock solution containing 2mM of interested drug Was
prepared and stored at —200 C. The stock solution Was diluted
5-time With DMSO to form 0.4 mM stock. 2pl 0.4 mM stock
Was added to 798 pl DMSO to form 1 pM Lactone form, or

form 1 pM 9-AC solution. After vortexing for 30 seconds,

using the equation:

ence: corrected total concentration minus free concentration.
All experiments Were run in triplicate.

Lactone Stability Studies

With or Without various Was spiked With 9-AC carboxylate to

device and centrifuged for 15 minutes at 4500 rpm. A 100 pl
aliquot of the ?ltrate Was added to a 600 pl ice-cold methanol,
vortexed and centrifuged at 8000 rpm for 30 seconds. A 500
pl aliquot of the supernatant Was removed and mixed With 25
pl 12 N HCl. Subsequently, 1 ml of Water Was added to the
suspension and the mixture Was vortexed and injected
(100 pl) onto the HPLC. The same protocol Was repeated With

The bound concentration Was obtained by calculating differ

Whole Blood, HSA or Human Plasma With or Without

Caprylic Acid
65

Weigh amount of caprylic acid and added to HSA, human
plasma and human Whole blood to form a certain concentra

tion of caprylic acid (1 mM, 2 mM, 10 mM, 25 mM, 50 mM

US 7,691,872 B2
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and 100 mM). For HSA and human plasma, incubate the HSA

What is claimed is:
1. A method for increasing the free drug levels of a camp

or human plasma With or Without caprylic acid at 370 C. and

adjust pH to7.4. For human Whole blood, it Will form partici
pate With caprylic acid When adjust pH With HCl or NaOH.
So, ?rst adjust pH a little below 7.4 and then add caprylic acid
to form pH 7.4 With caprylic acid in Whole blood. A 5 pl 0.4

tothecin drug that binds human serum albumin (HSA) during

mM interest drug solution Was added to 1995 pl of HSA
human plasma or human Whole blood that had previous been
incubated at 370 C. and adjusted to pH 7.4 to form a 1 pM
solution. At each respective time interval, a 150 pl volume
Was removed from the incubation tube and added to 600 pl of
ice-cold methanol (—200 C.), vortex-mixed for 20 s and cen
trifuged at 4000 g for 1 min. The supernatant Was directly
injected onto the HPLC column immediately. Aliquots Were

Wherein said HSA-binding compound is a phospholipid, so as
to block the camptothecin binding site on HSA and thus

taken and HPLC analyses Was performed at times of 1, 10, 20,
30, 60, 120 and 180 minutes, respectively. The fraction of

2. The method according to claim 1, Wherein the phospho
lipid is selected from the group consisting of lysolecithins and

lactone form Was calculated as:

oleoyllysophosphatidic acid.

anti-topoisomerase I-based therapy in humans, said method
comprising administering, to a human or animal patient in
need of said therapy, at least one HSA-binding compound,

reduce the binding of the camptothecin drug to HSA in human
blood or plasma so that the free drug levels of the camptoth
ecin drug Will be increased and so that greater levels of the

camptothecin Will reach the drug target at the treatment site,
Wherein the HSA-binding compound is administered sepa

rately from the camptothecin drug.

3. The method according to claim 1, Wherein the HSA

Fraction of lactone:lactone area/(lactone area+carboxylate
area*k), Where k is the response factor de?ned as the ratio of
molar ?uorescence intensities of the lactone to carboxylate
form.

20

4. The method according to claim 1, Wherein the HSA

binding compound is administered before, simultaneously
With, or after administration of the camptothecin drug.
5. The method according to claim 1, Wherein the binding of

In the Tables appended hereto, competition binding and
stability of 9AC, DB172, DB67 and SN38 With the presence
of various drugs is shoWn, including Table 1.1 (Protein bind
ing of 9AC carboxylate (1 pM) in HSA and human plasma)
and Table 1.2 (Protein binding of DB67 carboxylate (1 pM)

binding compound is administered intravenously or orally.

25

the HSA-binding compound to HSA occurs by covalent or
non-covalent means.

6. The method according to claim 1, Wherein the binding of
the HSA-binding compound to HSA results in the direct

in HSA and human plasma).

displacement of the camptothecin drug from its HSA binding
30

site.

7. The method according to claim 1, Wherein the binding of
Competition binding and stability of 9AC, DB172,

the HSA-binding compound to HSA results in the displace
ment of the camptothecin drug from its HSA binding site by

DB67 and SN38 With the presence ofvarious drugs

1. Competition binding
1.1 Protein binding of 9AC carboxylate (1 pM) in HSA and human plasma
Matrix

Compound added

HSA (1 mgml)

No

94.26 1 0.25

HSA (1 mgml)
HSA (1 mgml)
HSA (1 mgml)

Phenylbutazone (0.162 mM)
Ibuprofen (480 mM)
Caprylic acid (347 mM)

81.52 1 1.16
0.00 r 0.00
0.00 r 0.00

HSA (30 mg/ml)

No

HSA (30 mg/ml)
HSA (30 mg/ml)

Ibuprofen (10 mM)
Caprylic acid (10 mM)

Human plasma

No

Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma
Human plasma

Phenylbutazone (0.2 mM)
Aspirin (10 mM)
Warfarin-Na salt (10 mM)
L-Tryptophan (10 mM)
Ibuprofen (100 mM)
Ibuprofen (10 mM)
Ibuprofen (1 mM)
Caprylic acid (100 mM)
Caprylic acid (80 mM)
Caprylic acid (60 mM)
Caprylic acid (40 mM)
Caprylic acid (20 mM)
Caprylic acid (10 mM)
Caprylic acid (1 mM)

35

ecin drug is selected from the group consisting of camptoth
ecins that contain either an E-ring ot-hydroxy lactone phar
macophore or an E-ring [3-hydroxy lactone pharmacophore,

Percent 9AC bound

homocamptothecins, homosilatecans, 9-aminocamptothecin,
40

24.82 1 0.99
83.34 1 0.88

ylenedioXy-campto-thecin, 9-nitrocamptothecin, topotecan,

100.00 1 0.00

1 0.04
1 0.12
1 0.67
1 0.03
r 0.00
1 0.76
1 0.04
r 0.00
1 3.17
r 2.38
1 1.32
1 1.82
1 0.18
1 0.04

10-hydroxycamptothecin, 10,1 1 -methylenedioXy-camptoth
ecin, 9-nitro- 10,11-methylenedioxycamptothecin, 9-chloro
10, 1 1 -methylenedioXycamptothecin, 9-amino-10,1 1-meth

100.00 1 0.00

99.90
97.98
86.44
99.59
0.00
43.06
99.82
0.00
15.05
5.14
22.73
74.04
89.62
99.86

allosteric inhibition.
8. The method according to claim 1 Wherein the camptoth

45

and combinations of the above.
9. A method for improving the free lactone levels of at least
one camptothecin drug that binds in the carboxylate form to

HSA during anti -topoisomerase I-based therapy, said method
comprising administering, to a human or animal patient in
need of said therapy, at least one HSA-binding compound,
50

Wherein said HSA-binding compound is a phospholipid, so as
to block the camptothecin binding site on HSA and thus

reduce the binding of the camptothecin drug to HSA in human
blood or plasma so that the free lactone levels of the camp

1.2 Protein binding ofDB67 carboxylate (1 pM) in HSA and human

tothecin drug Will be increased in human blood or plasma and
so that greater levels of the camptothecin Will reach the drug
target at the treatment site, Wherein the HSA-binding com

plasma

pound is administered separately from the camptothecin

Matrix

Compound added

HSA (30 mg/ml)

No

99.22 1 0.23

HSA (30 mg/ml)
HSA (30 mg/ml)

Caprylic acid (100 mM)
Caprylic acid (10 mM)

39.09 1 0.88
75.52 1 0.69

Human plasma

No

98.58 1 0.09

Human plasma
Human plasma
Human plasma

Caprylic acid (100 mM)
Caprylic acid (10 mM)
Caprylic acid (1 mM)

53.39 1 1.64
78.81 1 0.31
96.40 1 0.06

55

drug.

Percent DB67 bound
60

10. The method according to claim 9, Wherein the HSA

binding compound is administered intravenously or orally.
11. The method according to claim 9, Wherein the HSA

binding compound is administered before, simultaneously
65

With, or after administration of the camptothecin agent.
12. The method according to claim 9, Wherein the binding
of the HSA-binding compound to HSA occurs by covalent or
non-covalent means.

US 7,691,872 B2
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13. The method according to claim 9, wherein the binding
of the HSA-binding agent to HSA results in the direct dis

21. The method according to claim 1, Wherein the HSA

binding compound has anti-tumor or tumoricidal activity.

placement of the camptothecin drug from its HSA binding

22. The method according to claim 1, Wherein the HSA

site.

binding compound has anti-HIV activity.

14. The method according to claim 9, Wherein the binding
of the HSA-binding agent to HSA results in the displacement
of the camptothecin drug from its HSA binding site by allos

23. The method according to claim 1, Wherein the HSA
binding compound that has the ability to enhance the anti
topoisomerase l-based therapy in addition to the ability to

teric inhibition.

bind HSA.
24. A method for improving the effectiveness of a thera

15. A method for enhancing the cellular uptake and cellular
concentration of the camptothecin drug that binds to HSA
during anti-topoisomerase l-based therapy, said method com
prising administering, to a human or animal patient receiving
said therapy, at least one HSA-binding compound, Wherein
said HSA-binding compound is a phospholipid, so as to block
the camptothecin binding site on HSA and thus reduce the
binding of the camptothecin drug to HSA in human blood or
plasma so that the cellular uptake and cellular concentration
of the camptothecin drug Will be enhanced in human blood or
plasma and so that greater levels of the camptothecin drug
Will reach the drug target at the treatment site, Wherein the

peutic treatment regimen using a camptothecin drug that
binds to HSA during anti-topoisomerase l-based therapy
comprising administering to a human or animal patient in

need of said therapy a HSA-binding compound, Wherein said
HSA-binding compound is a phospholipid, so as to block the

camptothecin binding site on HSA and thus reduce the bind
ing of the camptothecin drug to HSA in human blood or
plasma so that the effectiveness of the therapeutic treatment

regimen of the camptothecin drug Will be improved and so
that greater levels of the camptothecin Will reach the drug
20

target at the treatment site, Wherein the HSA binding com

HSA-binding compound is administered separately from the

pound is administered separately from the camptothecin

camptothecin drug.

drug.

16. The method according to claim 15, Wherein the HSA

25. The method according to claim 24 Wherein said thera

peutic treatment regimen comprises therapeutic treatment for

binding compound is administered intravenously or orally.
17. The method according to claim 15, Wherein the HSA

25

binding compound is administered before, simultaneously
With, or after administration of the camptothecin agent.
18. A method for enhancing the therapeutic effect of a
camptothecin drug that binds human serum albumin (HSA)
during anti-topoisomerase l-based therapy, said method com
prising administering, to a human or animal patient in need of
said therapy, at least one HSA-binding compound, Wherein

peutic treatment regimen comprises therapeutic treatment for
cancer.

30
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plasma so that the therapeutic effect of the camptothecin drug
Will be enhanced and so that greater levels of the camptoth

ecin drug Will reach the drug target at the treatment site,
Wherein the HSA-binding compound is administered sepa

rately from the camptothecin drug.
19. The method according to claim 18, Wherein the HSA

binding compound is administered intravenously or orally.
20. The method according to claim 18, Wherein the HSA

binding compound is administered before, simultaneously
With, or after administration of the camptothecin drug.

27. The method according to claim 1 Wherein the HSA
binding compound is administered in an amount of in an
amount of at least 0.1 mM.

28. The method according to claim 9 Wherein the HSA

said HSA-binding compound is a phospholipid, so as to block

the camptothecin binding site on HSA and thus reduce the
binding of the camptothecin drug to HSA in human blood or

AIDS.
26. The method according to claim 24 Wherein said thera

40

binding compound is administered in an amount of in an
amount of at least 0.1 mM.
29. The method according to claim 15 Wherein the HSA
binding compound is administered in an amount of in an
amount of at least 0.1 mM.
30. The method according to claim 18 Wherein the HSA
binding compound is administered in an amount of in an
amount of at least 0.1 mM.
31. The method according to claim 24 Wherein the HSA
binding compound is administered in an amount of in an
amount of at least 0.1 mM.

